Interactions between Δ9-tetrahydrocannabinol and heroin: Self-administration in rhesus monkeys

Behavioural Pharmacology

Volumn 23, Issue 8, 2012, Pages 754-761

  Li, Jun Xu ^a   Koek, Wouter ^a   France, Charles P ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

heroin; rhesus monkey; self administration 9 tetrahydrocannabinol

Indexed keywords

DIAMORPHINE; DRONABINOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SELF ADMINISTRATION; FEMALE; MALE; NONHUMAN; REINFORCEMENT; RHESUS MONKEY;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEROIN; MACACA MULATTA; MALE; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; TETRAHYDROCANNABINOL;

EID: 84870056858     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32835a3907     Document Type: Article

References (47)

1. Braida D, Iosué S, Pegorini S, Sala M (2004). Delta9- tetrahydrocannabinolinduced conditioned place preference and intracerebroventricular selfadministration in rats. Eur J Pharmacol 506:63-69. (Pubitemid 39575086)
2. Cichewicz DL (2004). Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317-1324. (Pubitemid 38045526)
3. Cooper ZD, Haney M (2010). Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology 211:141-148.
4. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G (2004). Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 491:137-148. (Pubitemid 38609471)
5. Dworkin SI, Mirkis S, Smith JE (1995). Response-dependent versus responseindependent presentation of cocaine: differences in the lethal effects of the drug. Psychopharmacology 117:262-266.
6. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA, et al. (2004). Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19:678-686. (Pubitemid 38241307)
7. Galici R, Pechnick RN, Poland RE, France CP (2000). Comparison of noncontingent versus contingent cocaine administration on plasma corticosterone levels in rats. Eur J Pharmacol 387:59-62. (Pubitemid 30035374)
8. Gardner EL, Vorel SR (1998). Cannabinoid transmission and reward-related events. Neurobiol Dis 5:502-533. (Pubitemid 29075848)
9. Greenwald MK, Stitzer ML (2000). Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59:261-275. (Pubitemid 30254241)
10. Guindon J, Hohmann AG (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8:403-421.
11. Gutstein H, Akil H (2005). Opioid analgesics. In: Brunton L, Lazo J, Parker K, editors. The pharmacological basis of therapeutics. Vol. 11: New York: McGraw-Hill; pp. 547-590.
12. Haney M (2007). Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 32:1391-1403. (Pubitemid 46788849)
13. Haney M, Bisaga A, Foltin RW (2003). Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 166:77-85. (Pubitemid 36286723)
14. Hosking RD, Zajicek JP (2008). Therapeutic potential of cannabis in pain medicine. Br J Anaesth 101:59-68. (Pubitemid 351881914)
15. Houser SJ, Eads M, Embrey JP, Welch SP (2000). Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, delta(9)-THC and anandamide. Brain Res 857:337-342. (Pubitemid 30107826)
16. Institute of Medicine (2011). Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: Committee on Advancing Pain Research, Care, and Education, Board on Health Sciences Policy, Institute of Medicine of the National Academies. The National Academies Press.
17. Iversen L, Chapman V (2002). Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2:50-55.
18. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010). Multicenter, double-blind, randomized, placebo-controlled, parallelgroup study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167-179.
19. Justinova Z, Tanda G, Munzar P, Goldberg SR (2004). The opioid antagonist naltrexone reduced the reinforcing effects of delta9-tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173:186-194. (Pubitemid 38591164)
20. Kraft B (2012). Is there any clinically relevant cannabinoid-induced analgesia? Pharmacology 89:237-246.
21. Lecca D, Cacciapaglia F, Valentini V, Acquas E, Di Chiara G (2007). Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. Psychopharmacology 191:653-667. (Pubitemid 46355877)
22. Li JX, McMahon LR, Gerak LR, Becker GL, France CP (2008). Interactions between delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology 199:199-208.
23. Maguire DR, Li J-X, Koek W, France CP (2012). Effects of 1-(2,3-dimethyl-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys. Psychopharmacology [Epub ahead of print].
24. McMahon LR, Amin MR, France CP (2005). SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. Behav Pharmacol 16:363-372. (Pubitemid 41404807)
25. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R (2003). The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105:79-88. (Pubitemid 37162476)
26. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. (2001). Functional interaction between opioid and cannabinoid receptors in drug selfadministration. J Neurosci 21:5344-5350. (Pubitemid 32622960)
27. Pashler H,Wixted JT (2002). Stevens' handbook of experimental psychology, 3rd ed., Vol. 4: Methodology in experimental psychology. New York: Wiley.
28. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63:569-611. (Pubitemid 32115433)
29. Rahn EJ, Hohmann AG (2009). Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 6:713-737.
30. Rios C, Gomes I, Devi LA (2006). Mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395. (Pubitemid 43882074)
31. Roberts JD, Gennings C, Shih M (2006). Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530:54-58. (Pubitemid 43037124)
32. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ (2006). Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51:773-781. (Pubitemid 44308340)
33. Seeling W, Kneer L, Büchele B, Gschwend JE, Maier L, Nett C, et al. (2006). Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain. Anaesthesist 55:391-400.
34. Smith FL, Fujimori K, Lowe J, Welch SP (1998). Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 60:183-191. (Pubitemid 28236629)
35. Smith PA, Selley DE, Sim-Selley LJ,Welch SP (2007). Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129-137. (Pubitemid 47379686)
36. Solinas M, Goldberg SR (2005). Involvement of mu-, delta-and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology 179:804-812. (Pubitemid 40767900)
37. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102. (Pubitemid 36734361)
38. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR (2005). Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30:2046-2057. (Pubitemid 43093504)
39. Takahashi RN, Singer G (1979). Self-administration of D9-tetrahydrocannabinol by rats. Pharmacol Biochem Behav 11:737-740.
40. Tanda G, Goldberg SR (2003). Cannabinoids: reward, dependence, and underlying neurochemical mechanisms -a review of recent preclinical data. Psychopharmacology 169:115-134. (Pubitemid 37129963)
41. Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3:1073-1074.
42. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH (1998). Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther 286:697-703. (Pubitemid 29003458)
43. Wachtel SR, de Wit H (2000). Naltrexone does not block the subjective effects of oral delta(9)-tetrahydrocannabinol in humans. Drug Alcohol Depend 59:251-260. (Pubitemid 30254240)
44. Welch SP (2009). Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 21:143-151.
45. Welch SP, Stevens DL (1992). Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10-18.
46. Welch SP, Thomas C, Patrick GS (1995). Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272:310-321.
47. Wojnicki FH, Bacher JD, Glowa JR (1994). Use of subcutaneous vascular access ports in rhesus monkeys. Lab Anim Sci 44:491-494.